Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | mitogen-activated protein kinase 1 | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 1 | 360 aa | 361 aa | 33.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0072 | 0 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0072 | 0 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0072 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0072 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0072 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0072 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0072 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0072 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0072 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0072 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0072 | 0 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0072 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0072 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0072 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.